Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study
By: Mafei Kang, Feng Xue, Shengyuan Xu, Jieqiong Shi and Yunyan Mo
Authors
Mafei Kang
Department of Medical Oncology, Affiliated Hospital of Guilin Medical University, Guangxi Guilin, China
Feng Xue
Department of Medical Oncology, Affiliated Hospital of Guilin Medical University, Guangxi Guilin, China
Shengyuan Xu
Department of Medical Oncology, Affiliated Hospital of Guilin Medical University, Guangxi Guilin, China
Jieqiong Shi
Department of Medical Oncology, Affiliated Hospital of Guilin Medical University, Guangxi Guilin, China
Yunyan Mo
Department of Medical Oncology, Affiliated Hospital of Guilin Medical University, Guangxi Guilin, China
Language: English
Page range: 405 - 410
Submitted on: Feb 16, 2023
Accepted on: Jun 15, 2023
Published on: Jul 26, 2023
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2023 Mafei Kang, Feng Xue, Shengyuan Xu, Jieqiong Shi, Yunyan Mo, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.